|
|
![horizontal rule](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/blkpixel.gif) |
Congressional
Testimony
|
|
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|
|
|
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
2003
November
- John M. Taylor, III,
November 20, 2003
Associate Commissioner for Regulatory
Affairs, Food and Drug Administration, before the Committee
on Commerce, Science and Transportation.
- Lester M.
Crawford, D.V.M, Ph.D. , November 19, 2003
Deputy Commissioner
of Food and Drugs before the Committee on Governmental Affairs.
- William Egan, November
13, 2003
Acting Director, Office
of Vaccine Research and Review, Center for Biologics Evaluation
and Research, before the Committee on Government Reform.
October
- John M.
Taylor, October 28, 2003
Associate Commissioner for
Regulatory Affairs Food and Drug Administration, before the
Committee on Commerce.
- Steven K.
Galson, M.D., M.P.H., October 23, 2003
Acting Director
of the Food and Drug Administration before the Senate Committee
on Health, Education, Labor and Pensions.
August
- Daniel E. Troy,
August 1, 2003
Chief of Counsel of the Food and Drug
Administration before the Committee on Judiciary, United States
Senate
July
- Mark B. McClellan,
M.D., Ph.D, July 24, 2003
Commissioner of Food and
Drugs before the Subcommittee on Commerce, Trade and Consumer
Protection and the Subcommittee on Oversight and Investigations,
Committee on Energy and Commerce, United States House of Representatives.
-
Mark B. McClellan, M.D., Ph.D, July 24, 2003
Commissioner
of Food and Drugs before the Committee on Health, Education,
Labor, and Pensions, United States Senate.
-
Janet Woodcock, M.D. , July 22, 2003
Director, Center
for Drug Evaluation and Research before the Senate Special
Committee on Aging.
- Lester M. Crawford,
D.V.M, Ph.D. , July 17, 2003
Deputy Commissioner
of Food and Drugs before the Committee on Environment
and Public Works.
- Theresa M. Mullin, Ph.D.,
July 10, 2003
Assistant Commissioner for Planning
before the Committee on Energy and Commerce.
- Mark B. McClellan,
M.D., Ph.D, July 9, 2003
Commissioner of Food and
Drugs before the Joint Economic Committee.
June
- William K. Hubbard,
June 24, 2003
Associate Commissioner for Policy, Planning
and John M. Taylor, III Associate Commissioner for Regulatory
Affairs before the Committee on Energy and Commerce, U.S.
House of Representative Hearing on“ A System Overwhelmed:
The Avalanche of Imported, Counterfeit, and Unapproved Drugs
in the U.S.”
- Daniel E. Troy, June
17, 2003
Chief Counsel before the Committee on the
Judiciary, United States Senate
- Lester M. Crawford,
D.V.M., Ph,D., June 17, 2003
Deputy Commissioner before
the Committee on Agriculture, U.S. House of Representatives
- William K. Hubbard,
June 12, 2003
Associate Commissioner for Policy, Planning
and Legislation before the Committee on Government Reform,
U.S. House of Representatives
May
- Jesse L. Goodman,
M.D., M.P.H., May 14, 2003
Director, Center for Biologics
Evaluation and Research before the Committee on Governmental
Affairs, U.S. Senate.
- Murray Lumpkin, M.D.,
M.Sc.,May 7, 2003
Principal Associate Commissioner,
FDA, before the Committee on Government Reform, U.S. House
of Representatives.
April
- William K. Hubbard,
April 3, 2003
Associate Commissioner for Policy, Planning
and Legislation before the Committee on Government Reform,
U.S. House of Representatives
March
- William K. Hubbard,
March 27, 2003
Associate Commissioner for Policy,
Planning and Legislation before the Committee on Government
Reform, U.S. House of Representatives
- John M. Taylor, March
10, 2003
Associate Commissioner for Regulatory Affairs
Food and Drug Administration, before the Subcommittee on Oversight
and Investigations Committee on Energy and Commerce House
of Representatives.
- Mark B. McClellan,
M.D., Ph.D., March 6, 2003
Commissioner of Food and
Drug Administration, House Agriculture, Rural Development,
FDA and related Agencies Appropriations Subcommittee Hearing.
|
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090117044017im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|